Outlooks for the biotech sector
The healthcare sector has been under a black cloud since the US Presidential Election last year, driven by concerns over drug pricing.
Concerns have been mounting in the run-up to the US election, particularly over Hillary Clinton's proposed clamp down on drug pricing, writes Carl Harald Janson.
Subject to shareholder approval
Latest roundup by QuotedData
Overuse of antibiotics around the globe has created a worrying increase in resistance to many commonly used drugs, writes Carl Harald Janson, lead manager on the International Biotechnology trust.
Biotech has fallen
Index plunged by more than 20% from peak